Ki 8751

• CAT Number: I002742
• CAS Number: 228559-41-9
• Molecular Formula: C24H18F3N3O4
• Molecular Weight: 469.42
• Purity: ≥95%
• Synonyms: 1-(2,4-difluorophenyl)-3-[4-(6,7-dimethoxyquinolin-4-yl)oxy-2-fluorophenyl]urea
• Target: VEGFR
• Solubility: DMSO ≥92mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL
• Storage: 3 years -20C powder
• IC50: 0.9 nM [1]
• InChI: InChI=1S/C24H18F3N3O4/c1-32-22-11-15-20(12-23(22)33-2)28-8-7-21(15)34-14-4-6-19(17(27)10-14)30-24(31)29-18-5-3-13(25)9-16(18)26/h3-12H,1-2H3,(H2,29,30,31)
• InChIKey: LFKQSJNCVRGFCC-UHFFFAOYSA-N
• SMILES: COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC(=C(C=C3)NC(=O)NC4=C(C=C(C=C4)F)F)F

Ki 8751 (Cat.No:I002742) is a potent and selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), a receptor involved in angiogenesis and tumor growth. By blocking VEGFR2 signaling, Ki 8751 inhibits the formation of new blood vessels and suppresses tumor growth. This compound holds promise as a therapeutic agent for various angiogenesis-related diseases, including cancer.

Reference

[1]. Kubo K, et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N/’-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem, 2005, 48(5), 1359-1366.
[2]. Tamura D, et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci, 2010, 101(6), 1403-1408.
[3]. Hasan MR, et al. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int J Cancer, 2011, 129(9), 2115–2123.